



WELCURE DRUGS & PHARMACEUTICALS LTD.

CIN: L24232DL1996PLC227773

Regd. Off.: Plot No. 55, Office No- 104 First Floor Vijay Block , Laxmi Nagar, East Delhi, Delhi-110092

Email: welcuredrugs227@gmail.com Website: www.welcuredrugs.com

Date: 18th June 2025,

To,
The General Manager,
Corporate Relationship Department,
BSE Limited, Phiroz Jeejeebhoy
Tower, Dalal Street, Mumbai — 400001,
Maharashtra, India

Reference: ISIN- INE331C01017; Scrip Code- 524661; Symbol- WELCURE

Subject: Intimation under Regulation 30 – ₹517 Crore Global Sourcing Mandate

Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”), we wish to inform the Exchange that **Welcure Drugs & Pharmaceuticals Limited (“Welcure”)** has executed a **definitive mandate for third-party sourcing and procurement services aggregating ~₹517 crore** with an overseas client, **Fortune Sagar Impex Company Limited, Thailand**.

Salient particulars

Particular	Details*
Mandate type	Fee-based sourcing & procurement of multiple finished-dosage SKUs (Ex-Works model).
Welcure’s revenue stream	Fixed 5 % commission on cost of goods; estimated service income ~₹25.85 crore to be recognised over FY 2025-26.
Execution window	Call-off basis, with mobilisation of the initial lot targeted immediately upon fulfilment of the customary prefunding milestones contemplated in the mandate; balance tranches expected to conclude by 30 September 2026.



WELCURE DRUGS & PHARMACEUTICALS LTD.

CIN: L24232DL1996PLC227773

Regd. Off.: Plot No. 55, Office No- 104 First Floor Vijay Block , Laxmi Nagar, East Delhi, Delhi-110092

Email: welcuredrugs227@gmail.com Website: www.welcuredrugs.com

Buyer responsibilities	Packaging, labelling, containerisation, insurance, freight and all destination-country regulatory clearances.
Related-party status	Not a related-party transaction; no promoter/ group entity interest.

The mandate enhances Welcure's fee-based portfolio without incremental balance-sheet exposure. The Company will provide further updates, as and when successive call-offs are activated, in accordance with SEBI LODR.

We request you to take the above on record and disseminate the information on the Exchange website for the benefit of stakeholders.

For Welcure Drugs & Pharmaceuticals Ltd.

Chintan Didawala Ganpat
Managing Director
DIN: 11088268